The most important challenge in Kidney Transplantation is to achieve the long-term survival of the transplanted organ, as 50% of patients will suffered a graft loss in the next 10 years following transplantation (unadjusted data).
To avoid the risk of graft rejection, patients require long term treatment with immunosuppressive drugs (IMS) but this treatment can also cause severe adverse events.
Currently IMS regimens are established empirically, based only on guidelines, monitoring of IMS plasmatic levels and side effects. The current strategy may lead to either under-immunosuppression (resulting in rejections) or over-immunosuppression (resulting in side effects).
The risk of graft rejection and the burden of adverse events are two of the most important challenges for the clinicians in the management of Kidney Transplant Patients. An adequate adjustment of immunosuppressive medications is needed to prevent them.
Currently there is no tool in clinical practice that allows to predict the individual immune response of each patient to the individual immunosuppressive drugs.